ACR Appropriateness Criteria® Supplemental Breast Cancer Screening Based on Breast Density

Weinstein, Susan P.; Slanetz, Priscilla J.; Lewin, Alan A.; Battaglia, Tracy A.; Chagpar, Anees B.; Dayaratna, Sandra; Dibble, Elizabeth H.; Goel, Mita Sanghavi; Hayward, Jessica H.; Kubicky, Charlotte Dai; Le‐Petross, Huong T.; Newell, Mary S.; Sanford, Matthew F.; Vincoff, Nina S.; Yao, Kathy; Moy, Linda

doi:10.1016/j.jacr.2021.09.002

Cited by 53 publications

(25 citation statements)

References 69 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MRI has many advantages, including that it is non-invasive, does not involve exposure to radiation, has high resolution, and can intuitively display the morphological and functional information of breast cancer, which will increase the accuracy of breast cancer diagnosis (14)(15)(16). Numerous studies (17)(18)(19)(20) have found that imaging groups can be used to predict the diagnosis, type, and lymph node metastasis of breast cancer. Breast MRI (21,22) has achieved satisfactory clinical results in this area.…”

Section: Discussionmentioning

confidence: 99%

Development of the prediction model based on clinical-imaging omics: molecular typing and sentinel lymph node metastasis of breast cancer

Wang

Zhang

et al. 2022

Ann Transl Med

View full text Add to dashboard Cite

Background: Imageology uses high-throughput and automatic computing methods to transform medical image data into quantitative data with feature space, and then makes accurate quantitative analysis, extracts features and builds models, which can intuitively observe the overall features of lesions and the surrounding tissues, and provide rich invisible information. At present, the research on the imaging features of dynamic contrast-enhanced (DCE) and diffusion-weighted imaging (DWI) to predict the molecular typing value has achieved results, but the imaging model based on DWI and DCE-magnetic resonance imaging (MRI) is not enough to predict the molecular subtypes, and the prediction value of the prediction model based on the three-dimensional volume of interest of the lesion to the four molecular subtypes of breast cancer has not been fully studied. Methods:The clinical data of 202 breast cancer patients at our hospital from October 2020 to November 2021 were collected. All patients were examined with multimodal MRI before surgery. Base on immunohistochemical recombinant Ki-67 protein (Ki-67), estrogen receptor (ER), human epidermal growth factor receptor-2 (HER-2) and progesterone receptor (PR) results, the tumors were divided into four types According to the results of the sentinel lymph node (SLN) biopsies, the patients were divided into SLN (+) and SLN (−) groups. 3-dimensional (3D) Slicer software was used to outline the region of interest (ROI), and AMni-Kinetics software was used for feature extraction. The imaging characteristics were screened using least absolute shrinkage and selection operator (LASSO)-Logistic regression model using R statistical software, and the receiver operating characteristic (ROC) curve was drawn using "pROC" software package to evaluate the prediction efficiency of the model. Results:The most efficacious model at predicting SLN (+) in breast cancer patients with different molecular subtypes and SLN metastasis was the model based on the imageological characteristics of fat inhibition, and T2-weighted imaging (T2WI), T1-weighted imaging + C (T1WI-C), and DWI combined sequences at the tumor + 2 mm periphery. AUC (sensitivity, specificity) of the validation group were 0.831 (0.856, 0.891), 0.832 (0.660, 0.877), 0.801 (0.772, 0.765), 0.904 (0.769, 0.873), and 0.819 (0.810, 0.500) respectively when the tumor was 2 mm around the tumor. Conclusions:The imaging features extracted from multi-parameter DWI, T1WI+C, and T2WI in breast cancer have certain value at predicting different molecular types and SLNs of breast cancer.^ ORCID: 0000-0001-8656-4461.

show abstract

Section: Discussionmentioning

confidence: 99%

Development of the prediction model based on clinical-imaging omics: molecular typing and sentinel lymph node metastasis of breast cancer

Wang

Zhang

et al. 2022

Ann Transl Med

View full text Add to dashboard Cite

show abstract

“…However, despite its good clinical performance, MRI is usually performed in second intention. Breast cancer screening by MRI is therefore reserved for women with a moderate to high risk of breast cancer (personal history, genetic predisposition, follow-up after breast conserving surgery or contralateral breast screening, mediastinal irradiation, as for Hodgkin’s disease, suspicion of specific lesions, such as atypical ductal hyperplasia (ADH), atypical lobular hyperplasia (ALH), and lobular carcinoma in situ (LCIS) ( 22 , 23 ). A first problem is the cost of MRI scans.…”

Section: Current Place Of Breast Mri In the Global Management Of Brea...mentioning

confidence: 99%

The road to breast cancer screening with diffusion MRI

Iima

Bihan

2023

Front. Oncol.

View full text Add to dashboard Cite

Breast cancer is the leading cause of cancer in women with a huge medical, social and economic impact. Mammography (MMG) has been the gold standard method until now because it is relatively inexpensive and widely available. However, MMG suffers from certain limitations, such as exposure to X-rays and difficulty of interpretation in dense breasts. Among other imaging methods, MRI has clearly the highest sensitivity and specificity, and breast MRI is the gold standard for the investigation and management of suspicious lesions revealed by MMG. Despite this performance, MRI, which does not rely on X-rays, is not used for screening except for a well-defined category of women at risk, because of its high cost and limited availability. In addition, the standard approach to breast MRI relies on Dynamic Contrast Enhanced (DCE) MRI with the injection of Gadolinium based contrast agents (GBCA), which have their own contraindications and can lead to deposit of gadolinium in tissues, including the brain, when examinations are repeated. On the other hand, diffusion MRI of breast, which provides information on tissue microstructure and tumor perfusion without the use of contrast agents, has been shown to offer higher specificity than DCE MRI with similar sensitivity, superior to MMG. Diffusion MRI thus appears to be a promising alternative approach to breast cancer screening, with the primary goal of eliminating with a very high probability the existence of a life-threatening lesion. To achieve this goal, it is first necessary to standardize the protocols for acquisition and analysis of diffusion MRI data, which have been found to vary largely in the literature. Second, the accessibility and cost-effectiveness of MRI examinations must be significantly improved, which may become possible with the development of dedicated low-field MRI units for breast cancer screening. In this article, we will first review the principles and current status of diffusion MRI, comparing its clinical performance with MMG and DCE MRI. We will then look at how breast diffusion MRI could be implemented and standardized to optimize accuracy of results. Finally, we will discuss how a dedicated, low-cost prototype of breast MRI system could be implemented and introduced to the healthcare market.

show abstract

“…Following these study results, the European Society of Breast Imaging recommends screening breast MRI every 2–4 years in women aged 50–70 years with extremely dense breasts (Table 1). 20 Before most of these studies were published, the recommendation of the ACR already acknowledged that breast MRI may be appropriate for screening women with dense breast tissue 107 . It is expected that screening recommendations of the ACR and other advisory bodies will further evolve based on the recent and upcoming data.…”

Section: Literature Searchmentioning

confidence: 99%

“…20 Before most of these studies were published, the recommendation of the ACR already acknowledged that breast MRI may be appropriate for screening women with dense breast tissue. 107 It is expected that screening recommendations of the ACR and other advisory bodies will further evolve based on the recent and upcoming data.…”

Section: Women At High Risk For the Development Of Breast Cancermentioning

confidence: 99%

Challenges and Changes of the Breast Cancer Screening Paradigm

Cömert

Gils

Veldhuis

et al. 2022

Magnetic Resonance Imaging

View full text Add to dashboard Cite

Since four decades mammography is used for early breast cancer detection in asymptomatic women and still remains the gold standard imaging modality. However, population screening programs can be personalized and women can be divided into different groups based on risk factors and personal preferences. The availability of new and evolving imaging modalities, for example, digital breast tomosynthesis, dynamic‐contrast‐enhanced magnetic resonance imaging (MRI), abbreviated MRI protocols, diffusion‐weighted MRI, and contrast‐enhanced mammography leads to new challenges and perspectives regarding the feasibility and potential harms of breast cancer screening. The aim of this review is to discuss the current guidelines for different risk groups, to analyze the recent published studies about the diagnostic performance of the imaging modalities and to discuss new developments and future perspectives. Level of Evidence 1 Technical Efficacy Stage 6

show abstract

ACR Appropriateness Criteria® Supplemental Breast Cancer Screening Based on Breast Density

Cited by 53 publications

References 69 publications

Development of the prediction model based on clinical-imaging omics: molecular typing and sentinel lymph node metastasis of breast cancer

Development of the prediction model based on clinical-imaging omics: molecular typing and sentinel lymph node metastasis of breast cancer

The road to breast cancer screening with diffusion MRI

Challenges and Changes of the Breast Cancer Screening Paradigm

Contact Info

Product

Resources

About